• The Medication Lecanemab was approved by the us Fda To Treat Alzheimer’s Disease in 2023.
  • Like All Medications, Lecanemab Comes with The Potential For Side Effects, Including Amyloid-Related Imaging Abnormalities (Aryan), Such as The Presence of Swelling Or Bleeding in the Brain.
  • The Clarity Ad Phase 3 Clinical Trial, Published in 2022, reported Vray Low Percentages of Participants Experience Aria.
  • A New Study Reconfirms The Clarity Ad Findings By Reporting that significant adverse, Such As Aria, Were Rare and Manageable in Real-World Use of Lecanemab for People Within The Earliest Stages of Alzheimer’s Disease.

While There Is Currently Does not cure for a Type of Dementia Calleed Alzheimer’s Disease, Over The Last Few Years, New Medications Have Been Introduced To Help Manage Disease Symptoms and Slow ITS PROGRESSION.

One Such Medication is Lecanemab, Distributed the Brand Name Leqembi, which was Approved by The US Fda in 2023.

Like All Medications, Lecanemab Has The Potential For Side Effects, Including Headaches, Dizziness, Muscle Aches, and Blurred Vision, as Well As a Vray Serry Serry Side Effect Known as Amyloid-Relaced Imaging Abnormalities (ARIA), Such as the witness of swelling or bleeding in the brain.

In November 2022, scientists published the results of the clarity ad phase 3 clinical trial aimed at determining the safety and efficacy of lecanemab in People with Early Alzheimer’s Disease. In that Study, Researchers Found 0.8% of Participants Experienced Aria-E (Edema/Effusion) and 0.7% Showed Signs of Aria-H (hemorrhage/HOSOSIDERIN DEPOSITION).

Now, New Study Recently Published in Jama Neurology RECONFIRMS The Clarity Ad Findings by Reporting That Significant Adverse Events-Such As Aria-Were Rare and Manageable in “Real-World” use of Lecanemab for People With Vray Mild Mild or Mild Alzheimer’s Disease.

What is Lecanemab?

For This Study, Recruited Refruited 234 People with Early Symptomatic Alzheimer’s Disease, With An Avege Age of About 74, Who Receive Lecanemab at The Outpatient Specialty Memory Clinic, Washington University Memory Diagnostic Center.

“Lecanemab is an antibody, a Kind of Protein normally in your body by your immune system,” Barbara Joy Snider, MD, PhD, A Professor of Neurology at Washu Medicine and Affiliated With The Knight Alzheimer’s Disease Research Center, and co-senior autor of this Study, explained to Medical News Today. “Antibodies Like Lecanemab Are Designed to have spegific targets and are manufactured, The administered to patients. Antibodies are used for many different conditions.”

Lecanemab and Amyloid Proteins

“Lecanemab was design to pick up Certain Types of Amyloid Protein. This is a protein that is made in your body and can bechome missfolded. When This Happens, it can interferent with brain activity and can form clumps street Amyloid Platques. This is What Happens in Alzheimer’s Disease. Amyloid Misfolding is not The Only Thing That Happens in the Brain In Alzheimer’s Disease, But It May Be One of the Cruple Steps in the Disease Process That Leads to Memory Loss and Dementia. “
– Barbara Joy Snider, MD, PHD

“In a Large Clinical Trial, People Who Were Treated With Lecanemab for 18 Months Had About 25-30% Less Decline in Their Memory and Thinking Than Did People Who Did Not Get The Medication,” Snider Said.

“It is important to note that the people treated with lecemab did have to loss in their memory and thinking, so the drarug did notar reverse or completely stop the memory loss, but it did significantly slow it down. Imaging Studies Showed that the Lecanemab Also Reduced and Subtimes Cleat Amyloid plaques in the brain, ”She Added.

1.8% of Earliest Stage Alzheimer’s Experience Aria Symptoms

AT the Study’s Conclusion, Researchers Found that 1.8% of participants at the Earliest Stage of Alzheimer’s Disease Showed Symptoms of Aria, Compared to 27% of participants with mile mile Alzheimer’s Disease.

“This finding emphasize the importance of early More Benefit and Fewer Side Effects.
– Barbara Joy Snider, MD, PHD

Snider and Her Team Also Discovered That of the 11 Participants Who Experienced Aria Symptoms, The Effects Mostly Disappeared Within A Few Months, and No Patients Died.

“This is very similar to What Was Seen in the Clinical Trial,” Snider Commented. “This is very reassuring and tells us that also drarugs can be used safely in a ‘real world’ clinic population.”

“We Will Continue to Follow Our Patients and Hope To Learn More About Side Effects of these Medications and About How Much They Slow Down Memory Loss,” She continues. “We look forward to sharing this information with other providers and to seeing larger studies this Treatments for Alzheimer’s Disease. “

More Research to Identify Increased Aria Risk Needed

MNT Spoke Withn Dickson, MD, PHD, A Neurologist at Massachusetts General Hospital, About This Study. Dickson Commented that the Study’s Findings are Generally in Line With What You have observed at His Center.

“While Aria Does Occur in Patients Treated With Lecanemab, It has manageable in Our Sub-Specialty Treatment Program,” I explained. “The Risk of Aria is off the Most significant consideration in choosing Patients’ Decions About Whether To Pursue Treatment With Anti-Amyloid Therapy Or Not.”

Lecanemab or Donanemab?

“Further Research to Identify Patients At Increased Risk for Aria, Specially Serv Make More Reported Decisions Regarding their Treatment Options.
– John Dickson, MD, PHD

Dickson Said That for Future Research, these weeks Should Be Examined in a Larger Patient Sample and That the Observation Time Should Be Extended.

“In general, The Risk of Aria Is Highest in the First Six Months of Treatment,” I explained. “While sub of the patients included in This Study Had More than Six Months of Treatment, Sub Patients Were Obraved For A Shorter Period Of Time. Thus, The Results of This Study May Underestimate The Number of Patients Who Will Develop Aria From The Study Population.”

Benefits vs. SIDE EFECTS FOR LECANEMAB

MNT Also Spoke with Manisha Parulekar, MD, FACP, AGSF, CMD, Director of the Division of Geriatrics at Hackensack University Medical Center in New Jersey, About This Research.

“While The Approval of Lecanemab offers a Glimmer of Hope for Alzheimer’s Patients, The Potential for Serious Side Effects Makes It A Complex Decision for prescribing Physicans,” Parulekar Said. “Careful Patient Selection, Monitoring, and Open Communication About the Benefits and Risks are Essential.”

“The Benefit Offered by Lecanemab is a Modest Slowing of Decline, not a cure or a reversal dramat. Risk Factors. ”
– Manisha Parulekar, MD, FACP, AGSF, CMD

“Identifying Patients Who Are Most Likely to Benefit from Lecanemab and Least Likely to Experience Seriousus Side Effects is crucial,” Parulekar Added. “Additional Safety Data and ‘Real World’ Experience (Are) Helpful for This Process.”